The biotech said during a meeting with investment bank Leerink and confirmed to BioPharma Dive that 13% of U.S. PNH patients on Soliris are in the company's OneSource support program for conversion to Ultomiris. Ultomiris (ravulizumab) is expected to be more cost-effective than its predecessor Soliris (eculizumab) as a treatment for atypical hemolytic uremic syndrome (aHUS) in the U.S., a new study indicates.. Those results are a positive sign that Ultomiris—which cleared just $24.6 million in first-quarter sales—will hit its 70% conversion target within the next two years. Ultomiris vs Soliris: atypical haemolytic uremic syndrome data at 26 weeks Ultomiris: Soliris : Study C08-002A/B: Study C10-004: Complete TMA response: 54%: 65%: 56%: Normalisation in platelet count: 84%--Normalisation in lactate dehydrogenase Data sources include IBM Watson Micromedex (updated 3 Mar 2021), Cerner Multum™ (updated 1 Mar 2021), ASHP (updated 3 Mar … ULTOMIRIS and aHUS. ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Ultomiris will cost $6,404 for a 300-milligram vial, RBC Capital Markets analyst Kennen MacKay said in a note. The switching is aided by Ultomiris’ slight cost savings to Soliris, at $6,404 per vial compared to $6,543 per vial for Soliris; ancillary cost reductions; and enhanced dosing schedule where patients take an infusion every eight weeks as opposed to every two weeks, they said. 18 years of age or older b. Documented baseline value for serum lactate dehydrogenase (LDH) is ≥1.5 times the upper (1) The active substance in Soliris, eculizumab, is a monoclonal antibody (a type of protein) that has been designed to attach to the C5 complement protein, which is a part of the body’s defence system called the ‘complement system’.. RELATED: FDA fast-tracks Alexion’s Ultomiris in 2nd Soliris indication. INDICATIONS AND USAGE ULTOMIRIS is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH). SOLIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. Soliris (eculizumab) Ultomiris (ravulizumab-cwvz) Soliris and Ultomiris are proven for the treatment of atypical Hemolytic Uremic Syndrome (aHUS). In other guidance, Alexion's metabolic business, which includes treatments Strensiq and Kanuma, is expected to pull in between $644 million and $680 million this year, increasing 18% from 2018. 1 The phase 3 study of ULTOMIRIS, administered intravenously every eight weeks in adults and every four to eight weeks in pediatric … Soliris is well-established, and physicians are comfortable with the medicine. Infection has been shown to amplify complement activity, which could have the potential to exacerbate a patient’s underlying condition in a complement-mediated disease. Soliris, including Boxed WARNING regarding serious and life-threatening meningococcal infections, at www.Soliris.net. RECENT MAJOR CHANGES Dosing and Administration (2.5) 10/2020 INDICATIONS AND USAGE PNH is a potentially life-threatening disease in which there is excessive breakdown of red blood cells, leading to problems such as anaemia (low red blood cell counts), kidney … Investors will be keen to know the sales figures of Alexion’s long-acting C5 complement inhibitor, Ultomiris. J1300-njection, I eculizumab, 10 mg C9052 Injection, ravulizumab-cwvz, 10 mg (ultomiris) J3590- Unclassified biologics (ultomiris) TYPE OF CRITERIA. 20. — Alexion’s Soliris® (eculizumab), another C5 inhibitor, is approved for the treatment of PNH, atypical hemolytic uremic syndrome, and generalized myasthenia gravis. While these drugs have established safety data, they both have prophylactic antibiotic administration requirements to prevent meningococcal disease during treatment. As of April 22, 22% of Soliris patients had switched over from the older drug, Alexion said, with the vast majority of new PNH patients starting on Ultomiris. Paroxysmal nocturnal hemoglobinuria (PNH) a. Under the ULTOMIRIS REMS, prescribers must enroll in the program (5.1). Investors will be keen to know the sales figures of Alexion’s long-acting C5 complement inhibitor, Ultomiris. Soliris ® (eculizumab), a complement inhibitor, is the first and only medication approved by the FDA to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive. By Hantson’s telling, Alexion is in the process of switching “from old to new” with its drug portfolio, and because of that he expected investors—and thus share prices—would eventually catch up … 2 We may cover Soliris®** (eculizumab) OR we may cover Ultomiris®** (ravulizumab) when all of the following criteria are met: 1. — Soliris is administered every two weeks for the treatment of PNH whereas Ultomiris is administered every eight weeks. Ultomiris is a medicine used to treat adults with paroxysmal nocturnal haemoglobinuria (PNH). Soliris and Ultomiris are medically necessary when all of the following criteria are met: Initial Therapy: o Documentation supporting the diagnosis of aHUS by ruling out both of the following: ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). NEXT REVIEW DATE 07/2020. 19. Enrollment in the ULTOMIRIS REMS program and additional information are available by telephone: 1-888-765-4747 or at www.ultomirisrems.com. The study, “ A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome,” was published in the Journal of Medical Economics. RxPA Ultomiris has the same complement C5 target as Soliris (eculizumab), interrupting a pathway leading to the destruction of red blood cells, but is longer-acting as it … Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. It can also be manufactured at higher capacity to meet global demand if it proves effective, says Alexion. August 13, 2019: Added criteria for Soliris for the expanded indication of treatment of NMOSD in adult patients who are anti-aquaporin-4 antibody positive. Ultomiris was FDA-approved in December 2018. So far, Ultomiris is off to a good start in achieving such a goal. With Soliris, A future with fewer relapses is possible. November 12, 2019: Added Ultomiris to the coverage criteria for aHUS based on updated package labeling. Ultomiris information includes side effects, interactions and indications. 1,12 . KS_PS_MDC_Soliris_and_Ultomiris_ProgSum_AR1020_r1220 Page 1 of 16 © Copyright Prime Therapeutics LLC. CRITERIA EFFECTIVE DATES: ORIGINAL EFFECTIVE DATE 06/2010. Please see Important Safety Information and full Prescribing Information and Medication Guide for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis, at www.ULTOMIRIS.com. In patients with PNH, aHUS, myasthenia gravis and NMOSD, the complement proteins are over-active and damage the patients’ own cells. They may need an extra nudge to try something new. Ultomiris is a better option to test than Soliris because it has simpler weight-based dosing and requires fewer infusions, reducing the burden on healthcare systems. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early. If you miss an ULTOMIRIS infusion, call your doctor right away. Alexion updated its 2019 guidance for Soliris and Ultomiris combined to between $4.02 billion and $4.07 billion, a 14% gain year over year. ULTOMIRIS is used to treat adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). Alexion said 8% have begun treatment with the drug. Alexion is investigating monoclonal antibody treatments Soliris (eculizumab) and Ultomiris (ravulizumab-cwvz) as potential therapeutics for COVID-19. The company, which has one of the world’s most expensive drugs in Soliris, has priced its next-generation product Ultomiris at around $458,000 per year, a 10% discount to its forerunner, in its first use, paroxysmal nocturnal haemoglobinuria (PNH). LAST REVIEWED DATE 07/2019. 12/2020 All Rights Reserved Effective: 03/01/2021 The drugmaker is trying to retain its stronghold in the PNH market by converting patients to its Soliris-successor Ultomiris, which won U.S. approval last year. ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). On average, the annual cost for Ultomiris maintenance doses is about $458,000, a discount of about 33% to the labeled maintenance dose of Soliris in aHUS, Alexion noted. Under the ULTOMIRIS REMS, prescribers must enroll in the program. ULTOMIRIS is a prescription medicine called a monoclonal antibody. ULTOMIRIS is the first and only long-acting C5 inhibitor that provides immediate and complete inhibition that is approved for atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Soliris_Ultomiris (eculizumab_ravulizumab) Policy Number: C4867-A. Ultomiris (ravulizumab-cwvz) is used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and hemolytic uremic syndrome. ULTOMIRIS is used to treat adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS). J CODE. Under the ULTOMIRIS REMS, prescribers must enroll in the program (5.1).